

Vitamin C and the Common Cold: A Retrospective Analysis of Chalmers' Review

Harri Hemilä, PhD and Zelek S. Herman, PhD

Department of Public Health, University of Helsinki, Finland (H.H.) and Linus Pauling Institute of Science and Medicine, Palo Alto, California (Z.S.H.)

Key words: Vitamin C, ascorbic acid, common cold, infection

In 1975 Thomas Chalmers analyzed the possible effect of vitamin C on the common cold by calculating the average difference in the duration of cold episodes in vitamin C and control groups in seven placebo-controlled studies. He found that episodes were 0.11 ± 0.24 (SE) days shorter in the vitamin C groups and concluded that there was no valid evidence to indicate that vitamin C is beneficial in the treatment of the common cold. Chalmers' review has been extensively cited in scientific articles and monographs. However, other reviewers have concluded that vitamin C significantly alleviates the symptoms of the common cold. A careful analysis of Chalmers' review reveals serious shortcomings. For example, Chalmers did not consider the amount of vitamin C used in the studies and included in his meta-analysis was a study in which only 0.025-0.05 g/day of vitamin C was administered to the test subjects. For some studies Chalmers used values that are inconsistent with the original published results. Using data from the same studies, we calculated that vitamin C (1-6 g/day) decreased the duration of the cold episodes by 0.93 ± 0.22 (SE) days; the relative decrease in the episode duration was 21%. The current notion that vitamin C has no effect on the common cold seems to be based in large part on a faulty review written two decades ago.

Key teaching points:

- In 1975 Thomas Chalmers published a meta-analysis of studies that have examined the role of vitamin C supplementation on common cold morbidity.
- Chalmers' paper is often cited as proof that vitamin C has no value in treating the common cold.
- The present study shows that Chalmers' analysis is fraught with errors and misleading data from the original studies.

INTRODUCTION

There exists a long-standing controversy concerning the possible efficacy of vitamin C in treating the common cold. The first reports indicating that vitamin C may be beneficial against the common cold were published in the 1930's and 40's [1-4]. The topic received wide publicity in the 1970's after Linus Pauling concluded from the published studies that vitamin C, in doses ≥ 1 g/day, significantly decreases both the incidence and the severity of the common cold, and wrote a popular book discussing the topic [3,4]. Pauling also carried out a meta-analysis [5], one of the very first in medicine, of the published studies in which he demonstrated a significant decrease in total

morbidity in the subjects ingesting vitamin C supplements ($p < 0.00003$). The claims of Pauling were not widely accepted within the medical community but they inspired a number of intervention studies to determine whether vitamin C does indeed have any actual effect. In fact, all 21 placebo-controlled studies published since 1970 which utilize ≥ 1 g/day of vitamin C have reported a decrease in the severity of symptoms or in the duration of the common cold episodes [6,7].

The general belief in conventional medical circles that vitamin C has no effect on the common cold [8-10] seems surprising since essentially all of the placebo-controlled studies carried out both before and after Pauling's conclusions have shown a beneficial effect [3-7]. We believe that the current

Dedicated to the memory of Professor Linus Pauling (1901-1994).

Address reprint requests to: Harri Hemilä, PhD, Department of Public Health, P.O. Box 21, 00014 University of Helsinki, Finland.

Journal of the American College of Nutrition, Vol. 14, No. 2, 116-123 (1995)

Published by the American College of Nutrition

conception that vitamin C does not affect the common cold can be traced largely to the review written by Chalmers in 1975 [11]. Chalmers carried out a meta-analysis of studies performed before 1975. From the results of seven studies, he calculated that the difference in the duration of episodes between the vitamin C and placebo groups was 0.11 ± 0.24 (SE) days, a difference considered by Chalmers to be "minor and insignificant", even though he noted that "in most studies the severity of symptoms was significantly worse in the patients who received the placebo." Based on his analysis, Chalmers stated "since there are no data on the long-term toxicity of ascorbic acid when given in doses of 1 g or more per day, it is concluded that the minor benefits of questionable validity are not worth the potential risk, no matter how small that might be [11]."

Chalmers' review has been cited twice as often as Pauling's meta-analysis (Table 1). Pauling's books have been extensively cited (Table 1), but this gives a highly misleading impression of their true scientific impact. In the current edition of the Recommended Dietary Allowances (RDA), Pauling's meta-analysis is mentioned, but Chalmers' review is referred to as proof that Pauling's conclusions were incorrect [8]. In monographs on infectious diseases Pauling's books and meta-analysis are rarely mentioned; rather, Chalmers' review is referred to as evidence that vitamin C has no effect on the common cold [9,10]. Chalmers' conclusions [11] of the published studies vary from that of other reviewers [3-7]. The present work analyzes the reasons for this apparent discrepancy.

ANALYSIS OF CHALMERS' REVIEW

Shortcomings in Chalmers' Table II

The argument in Chalmers' review is based primarily on his table II, which contains studies that he referred to as "reasonably well controlled studies." Chalmers' table II is reproduced here (Table 2) in order to show the various shortcomings in his analysis and to compare different ways of summarizing the data in order to estimate the treatment effect. A summary of the same studies by the present authors is presented as Table 3. Several of the numerical values presented by Chalmers are dubious for various reasons and these are underlined in Table 2.

Table 1. Citations of Reviews Analyzing the Vitamin C-Common Cold Studies [12]

Year	Chalmers' review [11]	Pauling's meta-analysis [5]	Pauling's two books [3,4]
1970-74	—	7	75
1975-79	24	15	123
1980-84	18	6	69
1985-89	14	2	35
1990-92	5	1	15
Total citations:	61	31	317

The data of the Karlowski study [17] are not correctly presented by Chalmers. Karlowski et al used four study groups and only one of these was a true placebo group; three other groups received vitamin C (3-6 g/day) according to different protocols (Table 4). The true placebo group in the study by Karlowski et al contained 46 subjects and the mean duration of the common cold episodes was 7.14 days (Table 4). However, Chalmers states that the number of subjects in the placebo group was 89 and the mean duration was 6.3 days (Table 2). Apparently, Chalmers totaled the number of subjects in groups 1 and 2 ($n = 89$), when in fact, group 2 received 3 g/day of vitamin C for therapy and cannot be considered a placebo group. Furthermore, the average for groups 3 and 4 (i.e. not groups 1 and 2) is 6.3 days. During the common cold episode, groups 3 and 4 were administered 3-6 g/day of vitamin C, but Chalmers gives their average as the duration in the "placebo" group (Table 2). Chalmers states that the number of subjects in the vitamin C group of Karlowski et al was 101 (Table 2) which is the sum of the subjects in groups 3 and 4 (Table 4). For the duration of cold episodes in the vitamin C group, Chalmers gives the value 6.8 days (Table 2) which is the average for groups 1 and 2 (group 1 was the true placebo group). Thus, when pooling the results, Chalmers combined the placebo group with one of the vitamin groups (groups 1 and 2), and two vitamin groups receiving different doses (groups 3 and 4). Thereafter, Chalmers exchanged the duration of the cold episodes for the two pooled groups (Tables 2 and 4).

Regarding the first study by Anderson et al [13], Chalmers displays the duration of colds according to the presence of symptoms (5% decrease with vitamin C; Table 2). However, Anderson et al observed a much greater effect on the outcome parameter "days indoors" (Table 3). This latter parameter apparently is more interesting for patients, since it is a measure of how much the common cold infections cause actual functional limitations. Accordingly, Chalmers' presentation of the duration of symptoms only, which did not reach statistical significance (Table 3), is misleading.

In case of the second study by Anderson et al [14], Chalmers gives the duration for a placebo group without indicating that there were actually two placebo groups in the study (Tables 2 and 3). There were great differences in these two placebo groups, these being a 14% difference in "days indoors" (Table 3) and a 30% difference in the duration of symptoms [14]. Furthermore, when the subjects were asked at the start of the trial for their recollection of "usual days indoors" during a typical common cold episode, placebo group #4 gave the largest value (2.57 days), and the other placebo group, #6, gave the smallest (1.97 days) among eight study groups, six of which were given vitamin C according to different protocols. The average of "usual days indoors" for three groups with regular vitamin C intake (≥ 1 g/day) was 2.34 days [14], which is 19% higher than the value for the placebo group #6. During the trial, the difference between the three vitamin C groups and the placebo group #6 was +13% (Table 3), which may suggest a

Table 2. Ascorbic Acid and the Common Cold: Reasonably Well-Controlled Studies according to Chalmers [11]

Study [reference]	Ascorbic acid		Placebo		Difference in duration (days)
	No. of subjects	Mean duration (days)	No. of subjects	Mean duration (days)	
Anderson et al 1972 [13]	407	<u>3.96</u>	411	<u>4.18</u>	0.22
Anderson et al 1974 [14]	583	<u>3.28</u>	578	<u>3.18</u>	-0.10
Coulehan et al 1974 [15]	<u>321</u>	<u>4.71</u>	<u>320</u>	<u>5.92</u>	1.21
Wilson et al 1973 [16]	<u>158</u>	<u>2.65</u>	<u>144</u>	<u>2.79</u>	0.14
Karlowski et al 1974 [17]	<u>101</u>	<u>6.80</u>	<u>89</u>	<u>6.30</u>	0.50
Cowan et al 1942 [2]	<u>233</u>	<u>1.10</u>	<u>194</u>	<u>1.60</u>	0.50
Cowan et al 1942 [2]	<u>227</u>	<u>1.70</u>	<u>120</u>	<u>1.00</u>	-0.70
				Mean ± SE:	0.11 ± 0.24
Ritzel 1961 [18]	139	<u>1.35</u>	140	<u>1.95</u>	0.60

Chalmers also listed the incidences of colds but these were left out to save space. Erroneous and misleading numerical values are underlined (see text and compare to Table 3).

small benefit when compared to the bias in the recollection. In any case, there seem to have been considerable biases in the

allocation of subjects into the eight groups and this problem was discussed by the authors [14]. Chalmers gives just two

Table 3. Ascorbic Acid and the Common Cold: Results from the Original Publications

Study [reference]	Vitamin C dose (g/day)	Ascorbic acid		Placebo		Difference in days	Relative difference (%)	Probability of difference (2-tailed)
		No. of subjects	Mean duration (days)	No. of subjects	Mean duration (days)			
<i>Dose ≥ 1 g/day</i>								
Anderson et al 1972 [13,19]	1+3	407	3.96* 1.04†	411	4.18 1.32	-0.22 -0.28‡	-5 -21‡	p < .05
Charleston & Clegg 1972 [20,21]	1	47	3.5	43	4.2	-0.7‡	-17‡	p < .05
Anderson et al 1974 [14]	1-5	860§	1.74†	285	1.76	-0.02	-1	
	1-5	860§	1.74†	293#	1.54	+0.20	+13	
Coulehan et al 1974 [15]	1	190**	4.95	192	5.65	-0.70‡	-12‡	p < .01††
	2	131**	4.44	128	6.29	-1.85‡	-29‡	p < .05††
Karlowski et al 1975 [17]	3‡‡	87	6.59	46	7.14	-0.55	-8	
	3+3	57	5.92	46	7.14	-1.22‡	-17‡	p < .05§§
Ritzel 1961 [5,18,22]	1	139	1.8	140	2.6	-0.8‡	-31‡	p < .05
					Mean ± SE:	-0.93 ± 0.22‡	-21 ± 3‡	p = 0.01‡
								p = 0.001‡ p < 0.000004
<i>Dose < 1 g/day</i>								
Cowan et al 1942 [2]	0.2	208##	0.58***	155	0.73	-0.15	-21	
Cowan et al 1942 [2]	0.025-0.05	170##	0.71***	94	0.42	+0.29	+69	
Wilson et al 1973 [16]	0.2	70†††	2.62	58	3.10	-0.48	-15	
Wilson et al 1973 [16]	0.2	88‡‡‡	2.68	86	2.48	+0.20	+8	

* Duration of symptoms.
 † Days confined to house.
 ‡ Mean ± standard error (SE) of the point estimates for studies marked with superscript; the p-value was calculated from the same point estimates with the 2-tailed t-test.
 § Study groups #1, #2, and #3 combined; all with ≥ 1 g/day of vitamin C.
 || Placebo group #4.
 # Placebo group #6.
 ** School children of upper classes received 2 g/day and of lower classes received 1 g/day.
 †† Significance for the total decrease in days of morbidity.
 ‡‡ Two 3 g/day groups are combined (cf. Table 4).
 §§ Calculated by these authors from Table 4 with the t-test; the significance of the difference was not calculated by Karlowski et al [17].
 ||| The probabilities of the studies marked with superscript (‡) have been combined with Fisher's method [23,24].
 ## The number of subjects who completed the study; Chalmers gives the number of subjects who began the study.
 Two study groups are combined in the 0.025-0.05 g/day results.
 *** Days lost from school per one episode; Chalmers gives the total number of days lost from school, i.e. over all episodes.
 ††† Schoolgirls.
 ‡‡‡ Schoolboys.

Table 4. Results from the Common Cold Study by Karlowski et al [17]

Group	Tablets		No. of subjects	Vitamin C during a cold (g/day)	Duration (days; mean \pm SE)	Difference (%)
	Prophylactic	Therapeutic				
1	P	P	46	0	7.14 \pm 0.46	
2	P	C	43	3	6.46 \pm 0.39	-10
3	C	P	44	3	6.71 \pm 0.53	-6
4	C	C	57	6	5.92 \pm 0.40	-17

Prophylactic tablets were given each day, i.e. also during the colds, and the therapeutic tablets were given for 5 days when the subject caught a cold. Tablets: P = placebo (lactose); C = vitamin C (ascorbic acid, 3 g/day). The data were taken from [11,17].

values derived from the study (Table 2) with no comments on the complexity of the study which may give a misleading impression of the reliability of the values presented.

In some of the publications dealing with the effect of vitamin C on the common cold two independent studies are reported simultaneously. In the case of the Cowan et al publication [2], Chalmers correctly presents the two studies separately. However, Coulehan et al [15] examined independently the effect of 1 g and 2 g daily vitamin C dosages on clinical episodes of illness, but Chalmers combines the two studies together (Tables 2 and 3). This gives more implicit emphasis to the two studies by Cowan et al. More importantly, when the estimate of the effect is calculated, the work of Cowan et al is thereby given a weighting factor of two, while the work of Coulehan et al gets a weighting of one.

Wilson et al also reported the results of two independent studies, one with boys and another with girls [16], and these too are presented as a single study by Chalmers (Tables 2 and 3). For girls, Wilson et al found a 15% decrease in the duration of episodes and a 45% decrease ($p < 0.05$) in the intensity of symptoms [16]. Vitamin C did not benefit boys (Table 3). In a more recent study Miller et al also found that vitamin C decreased the duration and severity in girls ($p < 0.05$) but not in boys [25]. In the latter study, the investigators observed that in boys given placebo, the vitamin C content of urine was increased during the study period, a phenomenon not observed in girls [25]. Thus, it is possible that the boys exchanged their tablets to some degree in the studies by Miller et al and Wilson et al. By combining the two studies of Wilson et al in his table II, Chalmers masked the marked benefit observed in girls, although Chalmers did remark in the text that in the studies by Wilson et al and by Coulehan et al, "the effects on symptoms seemed to be more striking in girls than in boys."

Chalmers states that the duration of episodes in the early study by Ritzel was 1.35 and 1.95 days in the vitamin and placebo groups, respectively (Table 2). In the original article, Ritzel gives values of 1.8 and 2.6 days, respectively [18]. Chalmers gives no explanation for this discrepancy [11].

In a footnote to his table II Chalmers noted that in the studies by Cowan et al there had been "blinding of subjects only" and that "subjects were assigned to ascorbic acid or placebo group alternately" [11]. However, Chalmers collected poor quality studies in his table I specifically, with a title

"neither randomized nor double blind", and it is not clear why he did not include the Cowan et al studies in that table. In contrast, Chalmers included the study by Charleston and Clegg [20], a single blind placebo-controlled study which found a significant benefit from the vitamin, in his table I. Technically the latter study is quite similar to the studies by Cowan et al except that a much larger dose of the vitamin was used (1 g/day). Thus, Chalmers was not consistent in selecting the studies for his table II. We have included Charleston and Clegg's study in our Table 3.

In retrospect, it is also possible to ask whether Chalmers employed the most appropriate statistical methods for analyzing the data he had available to him. For example, he did not weight the individual means with the number of subjects to arrive at a mean difference in duration per individual. Also, unlike Pauling [5], Chalmers does not report or analyze the p-values found in the studies [11].

Role of Vitamin C Intake in the Treatment and Control Groups

An important variable in vitamin C studies is the amount of the vitamin administered to the subjects but this variable was not taken into account by Chalmers. In fact, Chalmers included the study by Cowan et al in which only 0.025-0.05 g/day of vitamin C was given to the test group (Tables 2 and 3). If vitamin C does have biochemical effects resulting in the alleviation of common cold symptoms, a dose-response relationship would be apparent: very small dosages may be ineffective, whereas large dosages could produce moderate benefits. In addition, the subjects in the 0.025-0.05 g/day group of Cowan et al received several other vitamins simultaneously (vitamins A and D, thiamine, riboflavin, nicotinic acid) in addition to the small dose of vitamin C [2], and therefore any observed differences cannot be attributed specifically to vitamin C. For these reasons one might argue that this 0.025-0.05 g/day study should not have been included in Chalmers' analysis.

The optimum dose of vitamin C is not obvious [4,6,26]. Pauling selected studies for his meta-analysis in which more than 0.1 g/day of vitamin C was regularly used [5]. Furthermore, Pauling pointed out that the greatest benefit was observed in Ritzel's study in which the largest dose was used (1 g/day; [18]), and this led Pauling to propose 1 g/day or more for

the prevention and treatment of the common cold [3-5]. A dose-response effect is also seen in the studies Chalmers cited. Studies using at least 1 g/day of vitamin C show quite a consistent benefit, whereas studies with smaller doses show less consistent results (Table 3). Furthermore, Coulehan et al [15] and Karlowski et al [17] found a greater benefit in the study group given a larger dose of the vitamin (Table 3). Anderson et al compared the effect of 4 and 8 g/day of vitamin C when given, in several doses, only on the first day of illness [14]; the larger dose was consistently more beneficial when eight types of symptoms were measured. Thus, by including studies using small amounts of vitamin C (<1 g/day), Chalmers diluted the positive effects noted in studies using large amounts of vitamin C (≥ 1 g/day).

Furthermore, to test whether ≥ 1 g/day of vitamin C bestows benefits beyond those obtained on the RDA level of intake (0.06 g/day; [8]), the control group should not be allowed significant dietary intake of the vitamin. If the control group receives large amounts of vitamin C, a false negative result or a very small effect may result. A healthy diet containing large amounts of fruits and vegetables may provide more than 0.5 g/day of vitamin C, and in certain studies the control group apparently received large amounts of vitamin C in its diet [6,25]. Anderson et al [13] found that vitamin C supplementation was more beneficial to those who had a low intake of fruit juices compared to those with a high intake (a decrease of 48% and 22%, respectively, in total days indoors due to the common cold). The subjects of the Karlowski study [17] were employees of the NIH and therefore their dietary intake of vitamin C may have been much higher than the average in the United States; this could explain the rather small benefit observed when considering the high doses tested (Table 3). Thus, the dietary intake of vitamin C is an important modifying factor in the studies but it was not considered by Chalmers.

Calculation of an Estimate for the Benefit of Vitamin C

When Chalmers summarized the results for the effect of vitamin C on the duration of episodes, he calculated the average number of days saved by vitamin C administration per episode (Table 2). However, depending on the definition of disease (i.e. the outcome parameter) and on several other factors, the duration of the episode may be short or long, there being a ten-fold variation in the duration in different control groups in Table 3. When absolute values (days) are used in calculating the estimate of the effect, a great weight is given to studies with long duration of episodes. However, if a 3-day cold is shortened by 1 day, and a 6-day cold by 2 days, it seems inappropriate to conclude that the latter effect is twice the former. Instead, one may consider that both decreases are 33%. Thus, the absolute difference (days) used by Chalmers may not be the best parameter when comparing the various common cold studies.

Calculation of the relative effect may instead be a better means of comparing equivocal outcome parameters.

Furthermore, when Chalmers calculated the average effect, he segregated Ritzel's study from the other studies, even though he listed it in his table II. Chalmers argued that the study was not reliable since it lasted for a short period (1 week). However, a short duration may be compensated with a fairly large number of subjects and a fairly high incidence of cold episodes; both of which occurred in Ritzel's study which was carried out at a ski school in the Swiss mountains [18,22]. If Chalmers included the study by Ritzel in his calculation, calculated the differences in the study by Karlowski et al correctly, omitted the low-dosage studies (<1 g/day), and chose "days indoors" as the most relevant outcome parameter from Anderson's first study, vitamin C would have appeared much more effective.

In Table 3 we briefly present our analysis of the studies reviewed by Chalmers. We calculated the relative difference in the duration of colds to normalize the episode duration among the various studies. If the second study by Anderson et al [14] is excluded because of the technical problems discussed above, the mean decrease is 21% (median 19%). There are 13 studies not discussed by Chalmers in which a regular dose of ≥ 1 g/day has been used [6,7]; they have mostly been published after Chalmers' review. In these studies, the mean decrease in duration or severity of symptoms was 26% (median 22% [6,7]); therefore, Chalmers could have made a good estimate of the average benefit from vitamin C supplementation (≥ 1 g/day). However, as noted above, there is dose-dependency in the effect. The average benefit in all studies to date with 1 g/day has been 19% (median 13%) and in studies with 2-4 g/day it has been 29% (median 29%) [6,7].

Even though we consider the relative difference is a more meaningful parameter than the absolute difference (days), we also calculated the average for the absolute differences to allow explicit comparison of our Table 3 with Chalmers' table II. Vitamin C (1-6 g/day) would save 0.93 ± 0.22 (SE) days of illness per episode (Table 3). The latter value contrasts sharply with the average calculated by Chalmers, according to whom the difference between the vitamin C (0.025-6 g/day) and control groups is only 0.11 ± 0.24 (SE) days of illness per episode. Thus, from the studies that were known to Chalmers, an eight-fold higher estimate of the decrease in the duration of episode could have been obtained for vitamin C dosages suggested by Pauling [3-5]. In contrast to Chalmers' estimate, our estimate, 0.93 days saved per episode, significantly differs from zero ($p = 0.01$). It is noteworthy that the p-value for the estimate of the relative decrease in duration, —21%, is even lower ($p = 0.001$), apparently reflecting the benefits of the normalization procedure. Nevertheless, these p-values are conservative estimates of all the evidence. The individual p-values can be combined, for example, using Fisher's method [23,24], yielding a combined $p < 0.000004$.

The variability in the definition of the outcome parameter

makes us cautious regarding the significance of the exact estimate of the benefit. However, the magnitude of the average decrease (21%) by 1-6 g/day of the vitamin (or 29% by 2-4 g/day; [6,7]) seems to be potentially important considering that the common cold is the most frequent cause for absenteeism from work and school and one of the most common causes of visiting the physician [9,10]. Vitamin C is a very cheap nutrient, with no known harmful effects in the general population from 1 g/day even with long-term usage [27,28]. For example, none of the common cold intervention studies using ≥ 1 g/day of the vitamin, which have contained over 6000 subjects in total, have reported any significant harmful effects [6,7,13-20]. Research has indicated that our ancestors ate 0.4-2 g/day of vitamin C [29,30], and the gorilla, a close biological relative of humans, eats about 4 g/day of vitamin C [31]. Therefore, these doses are not unfamiliar to human physiology (i.e. not pharmacological) even though they are much larger than the RDA (0.06 g/day; [8]).

Placebo Effect is not a Valid Explanation of the Differences

In his review, Chalmers suggested that the benefit due to vitamin C reported in several studies could result from the placebo effect [11]. He based this suggestion on the study by Karlowski et al [17], in which the subjects who could correctly identify vitamin C reported greater benefit from the vitamin than those who could not identify it. In Karlowski's study, the placebo consisted of lactose, which can easily be distinguished from ascorbic acid by taste. However, in a large number of studies it has been explicitly reported that the placebo tablets were indistinguishable from the vitamin C tablets [2,6,7,13-15,20,22]. The tablets have often contained citric acid [13-15,20]. It appears unlikely that the placebo effect would explain the benefits observed when valid placebo tablets are used.

One may question whether Chalmers' suggestion of the role of the placebo effect is valid even in the case of the Karlowski study. After the study, Karlowski et al found by questionnaire that many of the subjects guessed correctly whether they were being given lactose or ascorbic acid [17]. The investigators reanalyzed their results by forming two groups from the subjects: those who correctly guessed their treatment, and those that did not try to guess their treatment. There were large differences in the duration of episodes between the vitamin and placebo groups among subjects who guessed their treatment correctly, but no marked differences in subjects who did not make the guess [17]. This led Chalmers to conclude that the observed differences were due to the placebo effect [11].

One should be cautious when dividing subjects into subgroups according to factors that may be associated with a possible real benefit and guessing the treatment is one of such factors. If vitamin C does produce a significant benefit certain people may identify the vitamin from its physiological effects. For example, Asfora initiated a double-blind study to test the

effects of 6 g/day of vitamin C on the common cold, but subjects receiving the vitamin could be identified by their clinical progress [32]. Thus, it is possible that in Karlowski's study, mild common cold symptoms led some subjects to correctly infer that they received vitamin C, and severe symptoms led to the inference that placebo was administered; whereas symptoms of medium severity led people not to make any guess of the treatment. In any case, the validity of the placebo should be examined before the study [13-15] rather than after its completion, as was the case in this poorly conducted study [17].

CONCLUSIONS

Chalmers' review of vitamin C and the common cold has been a cornerstone for the belief that the vitamin has no significant effects in reducing the severity of the common cold. The review has been used in several monographs as a basis for the conclusion that vitamin C is worthless for the treatment of the common cold [8-10]. We have shown that Chalmers' review contains serious and numerous errors. Therefore, the widely-accepted notion that vitamin C does not have any significant effect on the common cold is largely based on an unreliable review. After Chalmers' review was published, a large number of placebo-controlled double-blind studies have been carried out. Their results consistently and persuasively support the conclusion that vitamin C supplementation alleviates the symptoms of the common cold [6,7,33]. Moreover, the benefit due to vitamin C can now be rationalized physiologically. Vitamin C may protect against the reactive oxygen species that are produced, e.g. by phagocytes during a viral infection [6,34-37]. Also, vitamin C may enhance the proliferative responses of T-lymphocytes [37-46], and increase the production of interferon [47-51].

In this paper we show that even with the studies that were available to Chalmers, a more reasonable selection of the studies, corrections in his abstractions of the published results, and appropriate analysis would have indicated that vitamin C significantly decreases the duration of episodes of the common cold, a conclusion consistent with the studies carried out subsequent to the publication of Chalmers' review. Furthermore, in the period since the publication of Chalmers' review, the safety to the general population of long-term ingestion of large vitamin C doses has been established firmly [27,28]. Still, diarrhea and other gastrointestinal disturbances are sometimes associated with large doses (≥ 4 g/day) in healthy people [52]. However, people with the common cold infection can often ingest over 30 g/day of vitamin C without getting diarrhea [52], apparently due to changes in vitamin C metabolism [6,53]. Finally, there is much evidence suggesting that large therapeutic vitamin C doses which start early in the course of the common cold episode significantly decrease the severity of symptoms [1,6,17,32,33,52,54-57], but the evidence showing

the benefit of regular intake is much stronger as nearly all of the trials have studied the effects of regular intake.

ACKNOWLEDGMENTS

The authors are grateful to Professors Linus Pauling and Byron William Brown, Jr. for their perusal of the manuscript. We thank the reviewers for their helpful comments. This work was supported by the Juho Vainio Foundation (Finland) and the members of the Linus Pauling Institute.

REFERENCES

1. Ruskin SL: Calcium cevitamate in the treatment of acute rhinitis. *Ann Otol Rhinol Laryngol* 47:502-511, 1938.
2. Cowan DW, Diehl HS, Baker AB: Vitamins for the prevention of colds. *JAMA* 120:1268-1271, 1942.
3. Pauling L: "Vitamin C and the Common Cold." San Francisco: Freeman, 1970.
4. Pauling L: "Vitamin C, the Common Cold, and the Flu." San Francisco: Freeman, 1976 (expanded edition: New York: Berkley Books, pp 158-166, 1981).
5. Pauling L: The significance of the evidence about ascorbic acid and the common cold. *Proc Natl Acad Sci USA* 68:2678-2681, 1971.
6. Hemilä H: Vitamin C and the common cold. *Br J Nutr* 67:3-16, 1992.
7. Hemilä H: Does vitamin C alleviate the symptoms of the common cold? - a review of current evidence. *Scand J Infect Dis* 26:1-6, 1994.
8. National Research Council: "Recommended Dietary Allowances," 10th ed. Washington, DC: National Academy Press, pp 115-124, 1989.
9. Gwaltney JM: The common cold. In Mandell GL, Douglas RG, Bennett JE (eds): "Principles and Practice of Infectious Diseases," 3rd ed. New York: Churchill Livingstone, pp 489-493, 1990.
10. Liu C: The common cold. In Hoepflich PD, Jordan MC (eds): "Infectious Diseases. A Modern Treatise of Infectious Processes," 4th ed. Philadelphia: Lippincott, pp 288-293, 1989.
11. Chalmers TC: Effects of ascorbic acid on the common cold. An evaluation of the evidence. *Am J Med* 58:532-536, 1975.
12. Science Citation Index. Philadelphia: Institute for Scientific Information.
13. Anderson TW, Reid DBW, Beaton GH: Vitamin C and the common cold: a double-blind trial. *Can Med Assoc J* 107:503-508, 1972.
14. Anderson TW, Suranyi G, Beaton GH: The effect on winter illness of large doses of vitamin C. *Can Med Assoc J* 111:31-36, 1974.
15. Coulehan JL, Reisinger KS, Rogers KD, Bradley DW: Vitamin C prophylaxis in a boarding school. *N Engl J Med* 290:6-10, 1974.
16. Wilson CWM, Lori HS, Foster FG: The beneficial effect of vitamin C on the common cold. *Eur J Clin Pharm* 6:26-32, 1973.
17. Karlowski TR, Chalmers TC, Frenkel LD, Kapikian AZ, Lewis TL, Lynch JM: Ascorbic acid for the common cold. A prophylactic and therapeutic trial. *JAMA* 231:1038-1042, 1975.
18. Ritzel G: Critical analysis of the role of vitamin C in the prophylaxis and treatment of the common cold. *Helvetica Medica Acta* 28:63-68, 1961 (in German).
19. Anderson TW, Reid DBW, Beaton GH: Vitamin C and the common cold. *Can Med Assoc J* 108:133, 1973.
20. Charleston SS, Clegg KM: Ascorbic acid and the common cold. *Lancet* 1:1401-1402, 1972.
21. Clegg KM: Studies associated with ascorbic acid. *Acta Vitaminol Enzymol* 28:101-102, 1974.
22. Ritzel G: Ascorbic acid and the common cold. *JAMA* 235:1108, 1976.
23. Fisher RA: "Statistical Methods for Research Workers," 7th ed. London: Oliver and Boyd, pp 104-106, 1938.
24. Rosenthal R: Combining results of independent studies. *Psychol Bull* 85:185-193, 1978.
25. Miller JZ, Nance WE, Norton JA, Wolen RL, Griffith RS, Rose RJ: Therapeutic effect of vitamin C. A co-twin control study. *JAMA* 237:248-251, 1977.
26. Levine M, Morita K: Ascorbic acid in endocrine systems. *Vitamins Hormones* 42:1-64, 1985.
27. Rivers JM: Safety of high-level vitamin C ingestion. *Ann NY Acad Sci* 498:445-454, 1987.
28. Marks J: The safety of the vitamins. *Int J Vitam Nutr Res* 30(Suppl): 12-20, 1989.
29. Pauling L: Evolution and the need for ascorbic acid. *Proc Natl Acad Sci USA* 67:1643-1648, 1970.
30. Eaton SB, Konner M: Paleolithic nutrition: a consideration of its nature and current implications. *N Engl J Med* 312:283-289, 1985.
31. Bourne GH: Vitamin C and immunity. *Br J Nutr* 2:341-347, 1949.
32. Asfora J: Vitamin C in high doses in the treatment of the common cold. *Int J Vitam Nutr Res* 16(Suppl):219-234, 1977.
33. Pauling L: "How to Live Longer and Feel Better." New York: Freeman, 1986.
34. Turner RB: The role of neutrophils in the pathogenesis of rhinovirus infections. *Pediatr Infect Dis J* 9:832-835, 1990.
35. Oda T, Akaike T, Hamamoto T, Suzuki F, Hirano T, Maeda H: Oxygen radicals in influenza-induced pathogenesis and treatment with pyran polymer-conjugated SOD. *Science* 244:974-976, 1989.
36. Hemilä H: Vitamin C, neutrophils and the symptoms of the common cold. *Pediatr Infect Dis J* 11:779, 1992.
37. Anderson R, Smit MJ, Joone GK, van Staden AM: Vitamin C and cellular immune functions. *Ann NY Acad Sci* 587:34-48, 1990.
38. Siegel BV, Morton JI: Vitamin C and the immune response. *Experientia* 33:393-395, 1977.
39. Anthony LE, Kurahara CG, Taylor KB: Cell-mediated cytotoxicity and humoral immune response in ascorbic acid-deficient guinea pigs. *Am J Clin Nutr* 32:1691-1698, 1979.
40. Manzella JP, Roberts NJ: Human macrophage and lymphocyte responses to mitogen stimulation after exposure to influenza virus, ascorbic acid, and hyperthermia. *J Immunol* 123:1940-1944, 1979.
41. Anderson R, Oosthuizen R, Maritz R, Theron A, van Rensburg AJ: The effects of increasing weekly doses of ascorbate on certain cellular and humoral immune functions in normal volunteers. *Am J Clin Nutr* 33:71-76, 1980.
42. Fraser RC, Pavlovic S, Kurahara CG, Murata A, Peterson NS, Taylor KB, Feigen GA: The effect of variations in vitamin C intake on the cellular immune response of guinea pigs. *Am J Clin Nutr* 33:839-847, 1980.
43. Kennes B, Dumont I, Brohee D, Hubert C, Neve P: Effect of

- vitamin C supplements on cell-mediated immunity in old people. *Gerontology* 29:305-310, 1983.
44. Kristensen B, Thomsen PD, Palludan B, Wegger I: Mitogen stimulation of lymphocytes in pigs with hereditary vitamin C deficiency. *Acta Vet Scand* 27:486-496, 1986.
 45. Standefer JC, Vanderjagt D, Anderson RE, Garry PJ, Pogue L: Protective effect of ascorbate on radiation-sensitive thymidine uptake by lymphocytes. *Ann NY Acad Sci* 498:519-521, 1987.
 46. Oh C, Nakano K: Reversal by ascorbic acid of suppression by endogenous histamine of rat lymphocyte blastogenesis. *J Nutr* 118:639-644, 1988.
 47. Siegel BV: Enhanced interferon response to murine leukemia virus by ascorbic acid. *Infect Immunol* 10:409-410, 1974.
 48. Siegel BV: Enhancement of interferon production by poly(rI).-poly(rC) in mouse cell cultures by ascorbic acid. *Nature* 254:531-532, 1975.
 49. Geber WF, Lefkowitz SS, Hung CY: Effect of ascorbic acid, sodium salicylate, and caffeine on the serum interferon level in response to viral infection. *Pharmacology* 13:228-233, 1975.
 50. Schwerdt PR, Schwerdt CE: Effect of ascorbic acid on rhinovirus replication in WI-38 cells. *Proc Soc Exp Biol Med* 148:1237-1243, 1975.
 51. Dahl H, Degre M: The effect of ascorbic acid on production of human interferon and the antiviral activity in vitro. *Acta Pathol Microbiol Scand* 846:280-284, 1976.
 52. Cathcart RF: Vitamin C, titrating to bowel tolerance, anascorbemia, and acute induced scurvy. *Med Hypotheses* 7:1359-1376, 1981.
 53. Hume R, Weyers E: Changes in leucocyte ascorbic acid during the common cold. *Scott Med J* 18:3-7, 1973.
 54. Klenner FR: Massive doses of vitamin C and the virus diseases. *J Southern Med Surg* 113:101-107, 1951.
 55. Dalton WL: Massive doses of vitamin C in the treatment of viral diseases. *J Indiana State Med Assoc* 55:1151-1154, 1962.
 56. Regnier F: The administration of large doses of ascorbic acid in the prevention and treatment of the common cold. Part II. Review of *Allergy* 22:948-956, 1968.
 57. Anderson TW, Beaton GH, Corey PN, Spero L: Winter illness and vitamin C: the effect of relatively low doses. *Can Med Assoc J* 112:823-826, 1975.

Received June 1994; revision accepted October 1994.